• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mohs 显微外科治疗眼睑皮脂腺癌:一项多中心队列研究 360 例患者。

Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.

机构信息

Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.

Department of Ophthalmology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

出版信息

J Am Acad Dermatol. 2019 Jun;80(6):1608-1617.e1. doi: 10.1016/j.jaad.2018.12.053. Epub 2019 Jan 9.

DOI:10.1016/j.jaad.2018.12.053
PMID:30639290
Abstract

BACKGROUND

The decision to perform Mohs micrographic surgery (MMS) or wide local excision (WLE) for eyelid sebaceous carcinoma (SC) is controversial.

OBJECTIVE

To compare local recurrence, metastasis, and tumor-related mortality of patients with eyelid SC who were initially treated with MMS versus with WLE.

METHODS

A multicenter cohort study. Medical records were reviewed for factors associated with recurrence, metastasis, and tumor-related mortality. All eligible patients were followed up. The impact of initial surgical modality on the prognoses were determined by Cox analyses after control for all confounders.

RESULTS

Of the 360 patients included in this cohort, 115 (31.9%) underwent MMS as primary resection, whereas 245 (68.1%) underwent WLE. After a median follow-up period of 60.0 months, local recurrence was observed in 18 patients (15.7%) in the MMS group and 97 patients (39.6%) in the WLE group. Metastasis occurred in 9 patients (7.8%) who underwent MMS and 38 (15.5%) who underwent WLE. In all, 6 patients in the MMS group (5.2%) and 21 in the WLE group (8.6%) died of metastatic SC. Multivariable Cox regression indicated that compared with the WLE group, the MMS group exhibited more favorable local recurrence control (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.24-0.73; P = .002) but a comparable metastasis rate (HR, 1.38; 95% CI, 0.60-3.18; P = .453) and comparable tumor-related mortality (HR, 1.70; 95% CI, 0.59-4.93; P = .329). However, this beneficial effect became nonremarkable for patients with pagetoid intraepithelial neoplasia (HR, 1.73; 95% CI, 0.37-8.21; P = .488).

LIMITATIONS

Retrospective nature of the study.

CONCLUSION

MMS should be proposed for eyelid SC without orbital involvement to achieve recurrence control; however, this surgical procedure did not change the long-term outcomes in terms of metastasis or tumor-related mortality. Patients with pagetoid intraepithelial neoplasia may require adjuvant measures.

摘要

背景

对于眼睑皮脂癌(SC),行 Mohs 显微外科手术(MMS)或广泛局部切除术(WLE)的决策存在争议。

目的

比较眼睑 SC 患者初始接受 MMS 与 WLE 治疗后的局部复发、转移和肿瘤相关死亡率。

方法

一项多中心队列研究。对与复发、转移和肿瘤相关死亡相关的因素进行回顾性病历分析。所有符合条件的患者均进行随访。通过 Cox 分析,在控制所有混杂因素后,确定初始手术方式对预后的影响。

结果

在纳入的 360 例患者中,115 例(31.9%)患者作为初次切除术接受 MMS,245 例(68.1%)患者接受 WLE。中位随访 60.0 个月后,MMS 组 18 例(15.7%)患者和 WLE 组 97 例(39.6%)患者出现局部复发。MMS 组发生转移 9 例(7.8%),WLE 组转移 38 例(15.5%)。MMS 组共有 6 例(5.2%)患者和 WLE 组 21 例(8.6%)患者因转移性 SC 死亡。多变量 Cox 回归分析表明,与 WLE 组相比,MMS 组具有更好的局部复发控制效果(风险比[HR],0.42;95%置信区间[CI],0.24-0.73;P=0.002),但转移率(HR,1.38;95% CI,0.60-3.18;P=0.453)和肿瘤相关死亡率(HR,1.70;95% CI,0.59-4.93;P=0.329)相当。然而,对于存在 paget 样上皮内瘤变的患者,这种有益效果变得不明显(HR,1.73;95% CI,0.37-8.21;P=0.488)。

局限性

研究为回顾性。

结论

对于无眼眶受累的眼睑 SC,应建议采用 MMS 以实现复发控制;然而,这种手术方式并未改变转移或肿瘤相关死亡率的长期结果。对于存在 paget 样上皮内瘤变的患者,可能需要辅助措施。

相似文献

1
Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.Mohs 显微外科治疗眼睑皮脂腺癌:一项多中心队列研究 360 例患者。
J Am Acad Dermatol. 2019 Jun;80(6):1608-1617.e1. doi: 10.1016/j.jaad.2018.12.053. Epub 2019 Jan 9.
2
Mohs micrographic surgery versus wide local excision for sebaceous adenocarcinoma of the eyelid : Analysis of a national database.Mohs 显微外科手术与广泛局部切除术治疗眼睑皮脂腺腺癌:国家数据库分析。
J Plast Reconstr Aesthet Surg. 2019 Jun;72(6):1007-1011. doi: 10.1016/j.bjps.2019.02.009. Epub 2019 Mar 2.
3
Sebaceous carcinoma of the eyelids treated by mohs micrographic surgery: report of nine cases with review of the literature.莫氏显微外科手术治疗眼睑皮脂腺癌:9例报告并文献复习
Dermatol Surg. 2002 Jul;28(7):623-31. doi: 10.1046/j.1524-4725.2002.01306.x.
4
Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision.莫氏显微外科手术与广泛局部切除治疗原位黑色素瘤的疗效比较
JAMA Dermatol. 2017 May 1;153(5):436-441. doi: 10.1001/jamadermatol.2016.6138.
5
Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery.采用莫氏显微外科手术治疗的眼睑皮脂腺癌。
J Am Acad Dermatol. 2001 Jun;44(6):1004-9. doi: 10.1067/mjd.2001.113692.
6
Mohs micrographic surgery versus wide local excision for eyelid melanoma: An analysis of a national database.Mohs 显微描记手术与广泛局部切除术治疗眼睑黑色素瘤的比较:国家数据库分析。
J Plast Reconstr Aesthet Surg. 2022 Dec;75(12):4410-4415. doi: 10.1016/j.bjps.2022.08.076. Epub 2022 Aug 29.
7
Localized sebaceous carcinoma treatment: Wide local excision verses Mohs micrographic surgery.局限性皮脂腺癌的治疗:广泛局部切除术与Mohs 显微外科手术。
Dermatol Ther. 2020 Nov;33(6):e13991. doi: 10.1111/dth.13991. Epub 2020 Aug 6.
8
Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery.隆突性皮肤纤维肉瘤:广泛局部切除与莫氏显微外科手术对比
Cancer Treat Rev. 2008 Dec;34(8):728-36. doi: 10.1016/j.ctrv.2008.06.002. Epub 2008 Aug 5.
9
The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans.莫氏显微外科手术相较于传统广泛局部切除手术治疗隆突性皮肤纤维肉瘤的疗效。
Pan Afr Med J. 2019 Aug 13;33:297. doi: 10.11604/pamj.2019.33.297.17692. eCollection 2019.
10
Recurrence in Eyelid Sebaceous Carcinoma: A Multicentric Study of 418 Patients.眼睑皮脂腺癌的复发:418例患者的多中心研究
Invest Ophthalmol Vis Sci. 2024 Aug 1;65(10):4. doi: 10.1167/iovs.65.10.4.

引用本文的文献

1
Mohs micrographic surgery is non-inferior to wide local excision for disease specific survival in sebaceous carcinoma: analysis of the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021).对于皮脂腺癌的疾病特异性生存率,莫氏显微外科手术不劣于广泛局部切除:监测、流行病学和最终结果(SEER)数据库(2000 - 2021年)分析
Arch Dermatol Res. 2025 Jun 11;317(1):806. doi: 10.1007/s00403-025-04290-z.
2
Clinical presentation and prognostic factors of eyelid sebaceous carcinoma.眼睑皮脂腺癌的临床表现及预后因素
Jpn J Ophthalmol. 2025 May 25. doi: 10.1007/s10384-025-01187-2.
3
The Value of Orbital Exenteration for Eyelid Sebaceous Carcinoma in Stages II to IV: A Cohort Study of 78 Patients.
眼眶内容剜除术对Ⅱ至Ⅳ期眼睑皮脂腺癌的价值:一项78例患者的队列研究
Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):40. doi: 10.1167/iovs.66.1.40.
4
Recurrence in Eyelid Sebaceous Carcinoma: A Multicentric Study of 418 Patients.眼睑皮脂腺癌的复发:418例患者的多中心研究
Invest Ophthalmol Vis Sci. 2024 Aug 1;65(10):4. doi: 10.1167/iovs.65.10.4.
5
Masqueraded sebaceous gland carcinoma of the lower eyelid in a young pregnant patient.一名年轻孕妇下睑皮脂腺癌伪装病例
Wien Klin Wochenschr. 2025 Jan;137(1-2):13-15. doi: 10.1007/s00508-024-02349-x. Epub 2024 Apr 18.
6
Sebaceous carcinoma: an updated review of pathogenesis, diagnosis, and treatment options.皮脂腺癌:发病机制、诊断和治疗选择的最新综述。
Arch Dermatol Res. 2023 Dec 19;316(1):55. doi: 10.1007/s00403-023-02747-7.
7
Diagnosis and treatment of malignant eyelid tumors.恶性眼睑肿瘤的诊断与治疗。
Ophthalmologie. 2024 Jan;121(Suppl 1):33-39. doi: 10.1007/s00347-023-01945-y. Epub 2023 Oct 18.
8
[Diagnosis and treatment of malignant eyelid tumors].[恶性眼睑肿瘤的诊断与治疗]
Ophthalmologie. 2023 Mar;120(3):262-270. doi: 10.1007/s00347-023-01820-w. Epub 2023 Feb 9.
9
Mohs micrographic surgery for periocular skin cancer: a single-institution experience.Mohs 显微外科治疗眼周皮肤癌:单机构经验。
Arch Dermatol Res. 2023 Jul;315(5):1181-1186. doi: 10.1007/s00403-022-02481-6. Epub 2022 Dec 5.
10
Mohs micrographic surgery in rare cutaneous tumors: a retrospective study at a Brazilian tertiary university hospital.罕见皮肤肿瘤的 Mohs 显微外科手术:巴西一所三级大学医院的回顾性研究。
An Bras Dermatol. 2023 Jan-Feb;98(1):36-46. doi: 10.1016/j.abd.2022.01.009. Epub 2022 Nov 8.